What drove the MDG1.F stock spike today?

The intraday rise to **€0.0392** came on heavy volume and renewed speculation around Medigene AG’s liquidation process and the upcoming 26 Mar 2026 company update. Low float and small market cap magnified the move.

What is Meyka AI’s forecast for MDG1.F stock?

Meyka AI's forecast model projects a conservative base‑case of **€0.30** for MDG1.F stock, implying about **665.31%** upside from **€0.0392**. Forecasts are projections and not guarantees.

Is MDG1.F stock a buy for long‑term investors?

Long‑term buying depends on liquidation outcomes. MDG1.F stock carries binary risk: possible recovery of cash per share versus near‑zero equity value. Investors should research filings and size allocations carefully.

How should traders manage risk in MDG1.F stock?

Given MDG1.F stock’s low liquidity and volatility, use strict position limits, set stop losses, and avoid large blocks. Watch the 26 Mar 2026 announcement and official liquidation notices for material catalysts.

DE Stocks

MDG1.F Medigene AG (XETRA) +35% intraday on 17 Mar 2026: check liquidation value

ByHuzaifa Zahoor March 17, 2026March 17, 2026

MDG1.F stock jumped 35.17% intraday to €0.0392 on XETRA on 17 Mar 2026, driven by heavy volume and renewed attention to the company’s liquidation process. Traders executed 29,701 shares versus an average of 12,630, sending the penny stock well above its open of €0.0332. The move highlights speculative flows in a low‑cap biotech in liquidation and forces a reassessment of potential recovery value per share versus current market pricing.